Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. April 2018 16:00 ET | Quelle: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Reports First Quarter 2018 Business Update and Financial Results

- APL-2 in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) On Track to Advance into Phase 3 Trials in 2H18 - - Cash Position of $152.9 Million at Quarter-End; April 2018 Public...
23. April 2018 18:20 ET | Quelle: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Closing of Offering of Common Stock

CRESTWOOD, Ky. and WALTHAM, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
18. April 2018 21:26 ET | Quelle: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Pricing of Offering of Common Stock

CRESTWOOD, Ky. and WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
16. April 2018 17:12 ET | Quelle: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Proposed Offering of Common Stock

CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
16. April 2018 09:23 ET | Quelle: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab

CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
19. März 2018 16:30 ET | Quelle: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

- Initiation of Phase 3 Programs in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) Planned for 2018; Phase 2 Proof-of-Concept (POC) Data Anticipated in Autoimmune Hemolytic...
23. Februar 2018 07:00 ET | Quelle: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
22. Februar 2018 08:44 ET | Quelle: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy

CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
02. Januar 2018 07:00 ET | Quelle: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference

CRESTWOOD, Ky. and CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
20. Dezember 2017 17:30 ET | Quelle: Apellis Pharmaceuticals, Inc.

Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2

CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...

Vorherige Seite